Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral) for early stage HER2-overexpressed/amplified breast cancer, neratinib in combination with capecitabine for advanced or metastatic HER2-positive breast cancer, and for HER2 mutation-positive solid tumors. Its products also include PB272 (neratinib, intravenous), and PB357.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. 

We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

COM:PUMABIOTECHNOLOGY

Puma Biotechnology, Inc.

Last Close

2.79

30/10 20:00

Market Cap

146.65M

Beta: -

Volume Today

130.90K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

competitor of

Metrics